Right heart function is the main determinant of prognosis in pulmonary arterial hypertension
(PAH). At present, no treatments are currently available that directly target the right ventricle …

There is a strong rationale for combining therapies to simultaneously target three of the key
pathways implicated in the pathogenesis of pulmonary arterial hypertension (PAH) …

Pulmonary arterial hypertension (PAH) is a rare and severe clinical condition characterized
by a progressive increase of pulmonary vascular resistance leading to right ventricular …

Background Pulmonary hypertension (PH) is a well-known independent prognostic factor in
chronic obstructive pulmonary disease (COPD) and a sufficient criterion for lung transplant …

Trauma-induced coagulopathy (TIC) is a recently described condition which traditionally has
been diagnosed by the common coagulation tests (CCTs) such as prothrombin …

Introduction Exercise variables determined in patients with pulmonary arterial hypertension
(PAH) at the time of diagnosis, predict survival. It is unknown whether upon treatment …

BACKGROUND: Delayed postexercise heart rate recovery (HRR) has been associated with
disability and poor prognosis in chronic cardiopulmonary diseases. The usefulness of HRR …

Introduction Pulmonary arterial hypertension (PAH) is a progressive and life-threatening
disease. Approved treatment options currently primarily target abnormal cell signaling …

The Division of Lung Diseases of the NHLBI and the Cardiovascular Medical Education and
Research Fund held a workshop to discuss how to leverage the anticipated scientific output …

Introduction: Macitentan is a novel dual endothelin receptor antagonist (ERA) showing
sustained receptor occupancy. In vitro and in vivo animal studies have demonstrated its …